PureTech Health (LON:PRTC) Shares Up 14.2% - Should You Buy?

Key Points

• PureTech Health's shares surged 14.2% during mid-day trading, rising to GBX 121.50 ($1.64) after previously closing at GBX 106.40 ($1.43).
• Approximately 9 million shares were traded, marking an increase of 1,053% from the average daily volume of 781,543 shares.
• Insider Bharatt Chowrira acquired 167,739 shares at a cost of £1 per share, indicating confidence in the company's future performance.

PureTech Health plc (LON:PRTC - Get Free Report)'s stock price rose 14.2% on Saturday . The stock traded as high as GBX 123.80 ($1.67) and last traded at GBX 121.50 ($1.64). Approximately 9,013,305 shares changed hands during trading, an increase of 1,053% from the average daily volume of 781,543 shares. The stock had previously closed at GBX 106.40 ($1.43).

PureTech Health Price Performance

The stock has a market capitalization of £300.17 million, a PE ratio of 730.59 and a beta of 1.02. The company has a quick ratio of 2.51, a current ratio of 3.68 and a debt-to-equity ratio of 45.82. The stock's 50 day moving average price is GBX 129.46 and its 200-day moving average price is GBX 129.72.

Insider Transactions at PureTech Health

In other PureTech Health news, insider Bharatt Chowrira acquired 167,739 shares of the company's stock in a transaction on Thursday, July 3rd. The shares were bought at an average cost of GBX 1 per share, for a total transaction of £1,677.39. Insiders own 13.13% of the company's stock.

PureTech Health Company Profile

PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule.